Formulation: A solid
Formal Name: N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide, monosodium salt
Purity: ≥98%
Formula Markup: C20H23N2O5S • Na
Formula Weight: 426,5
Shelf life (days): 730
CAS Number: 256373-96-3
Notes: MCC950 is an inhibitor of NOD-like receptor protein 3 (NLRP3) inflammasome activation.{28329} It inhibits ATP-induced IL-1β release in LPS-primed mouse bone marrow-derived macrophages (BMDMs; IC50 = 7.5 nM), as well as cytosolic LPS-induced IL-1β release in Pam3CSK4-primed mouse BMDMs at 0.1 and 1 µM, indicating inhibition of both canonical and non-canonical NLRP3 inflammasome activation, respectively. MCC950 is selective for NLRP3 over NLRC4 and absent in melanoma 2 (AIM2) inflammasomes and does not inhibit LPS-induced NLRP3 priming in mouse BMDMs at 10 µM. It reduces ox-LDL-induced increases in caspase-1 activity and inhibits pyroptosis in THP-1 macrophages when used at a concentration of 1 µM.{62582} MCC950 (10 mg/kg) reduces myocardial fibrosis in mice following myocardial infarction induced by left coronary artery ligation.{62583} It improves forelimb grip strength and reduces spinal edema in a mouse model of spinal crush injury at the same dose.{62584}
English
Deutsch
